Citigroup
NVNO

Citigroup’s enVVeno Medical NVNO Stock Holding History

Citigroup’s Portfolio NVNO Stock Details NVNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1
Closed -$10 – 6090
2026
Q1 		$10 Buy
+1
New +$11 ﹤0.01% 5740

Other funds holding NVNO

KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
WIM
Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 57.61% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Citigroup's NVNO Position: Q2 2026 in Review

Citigroup sold out of enVVeno Medical (NVNO) in Q2 2026, closing a stake of 1 share — an estimated $10 sold.

Citigroup first reported a position in NVNO in Q1 2026 and held it in 1 quarter. The position peaked at $10 in Q1 2026. 17 funds tracked by Wall St. Rank hold NVNO as of Q2 2026.

  • Citigroup reported no remaining enVVeno Medical position as of Q2 2026 after selling out during the quarter.
  • Citigroup sold 1 enVVeno Medical share in Q2 2026, an estimated $10.
  • Citigroup first reported a position in enVVeno Medical in Q1 2026 and held it in 1 quarter.
  • Citigroup's enVVeno Medical position peaked at $10 in Q1 2026.
  • 17 funds tracked by Wall St. Rank held enVVeno Medical as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.